BioSpace News Archive

Stereotaxis announced that physicians at Overland Park Regional Medical Center launched and successfully completed the first procedures using the advanced Genesis Robotic Magnetic Navigation System.

This year marks the fifth anniversary of the Gilead COMPASS Initiative®, a 10-year, more than $100 million commitment to addressing the HIV epidemic in the Southern United States.

XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, double-blind, placebo-controlled clinical study for Natrunix in combination with chemotherapy for treating pancreatic cancer.

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the Journal of Cosmetic Dermatology published results from a year-long, post-hoc analysis of patient-reported outcomes (PROs) from two Phase 3 clinical studies evaluating the impact of onabotulinumtoxinA (BOTOX® Cosmetic) on upper facial lines (UFLs) in adults new to toxin treatment.

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Avidity management will be participating at the following upcoming conferences.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is providing this update on the status of the Company’s anticipated submission of an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for its planned U.S. Phase 1b Hypertension Clinical Trial designated as HYPER-H23-1.

Jacobio Pharma, a clinical-stage oncology company focusing on undruggable targets, announced its 2023 interim results.

Urotronic, Inc. today announced the publication of positive data from its PINNACLE clinical trial evaluating the Optilume® BPH Catheter System’s safety, effectiveness and durability in treating lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).

Pfizer Inc. and BioNTech SE announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing authorization for the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine administered as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history.

Waters Corporation announced that Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Bank of America Global Healthcare Conference in London on Wednesday, September 13th, 2023 at 8:20AM Eastern Time